STAG2 and glioblastoma: A similar increased sensitivity to PARP inhibition was observed in STAG2-depleted glioblastoma [15,163], Ewing sarcoma [15], hTERT-positive retinal pigmented epithelial cells [15] and in certain STAG2 mutant leukemia cells [150].